[1]杨永德,周焱琳.浸润性乳腺癌组织中miRNA-206表达与临床病理及预后的关系[J].现代检验医学杂志,2019,34(04):45-48.[doi:10.3969/j.issn.1671-7414.2019.04.011]
　YANG Yong-de,ZHOU Yan-lin.Relationship between Expression of miRNA-206 and Clinical Pathology and Prognosis in Invasive Breast Cancer[J].Journal of Modern Laboratory Medicine,2019,34(04):45-48.[doi:10.3969/j.issn.1671-7414.2019.04.011]
点击复制

浸润性乳腺癌组织中miRNA-206表达与临床病理及预后的关系()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第34卷
期数:
2019年04期
页码:
45-48
栏目:
论著
出版日期:
2019-08-20

文章信息/Info

Title:
Relationship between Expression of miRNA-206 and Clinical Pathology and Prognosis in Invasive Breast Cancer
文章编号:
1671-7414(2019)04-045-04
作者:
杨永德; 周焱琳
(重庆三峡中心医院,重庆 404000)
Author(s):
YANG Yong-de; ZHOU Yan-lin
(Chongqing Three Gorges Central Hospital,Chongqing404000,China)
关键词:
浸润性乳腺癌;  微RNA-206;  病理特征
分类号:
R737.9; R730.43
DOI:
10.3969/j.issn.1671-7414.2019.04.011
文献标志码:
A
摘要:
目的 探究浸润性乳腺癌组织中miRNA-206表达与临床病理及预后的关系。方法 选择2014年3月～2016年5月的121例浸润性乳腺癌患者作为研究对象。采用RT-qPCR法检测癌组织中miRNA-206的表达情况,并分析其与临床病理及预后的关系。结果 浸润性乳腺癌组织中miRNA-206的相对表达量高于癌旁组织[(0.75±0.23)vs(0.12±0.06)],差异有统计学意义(t=27.761,P<0.001)。浸润性乳腺癌组织中miRNA-206相对表达量与TNM分期和淋巴结转移个数有关(χ2=12.861,2.309,均P<0.05)。miRNA-206高表达组1a,2a和3a生存率均低于miRNA-206低表达组(78.18%,67.27%和56.36%vs 89.39%,81.82%和75.76%)。miRNA-206高表达组患者平均生存时间低于低表达组[26.87个月(95%CI:23.80～29.95)vs 31.52个月(95%CI:29.34～33.69),差异有统计学意义(χ2=5.570,P=0.018)。Cox单因素及多因素分析结果显示TNM分期、淋巴结转移及miRNA-206相对表达量与浸润性乳腺癌患者预后密切相关(P<0.05)。结论 miRNA-206在浸润性乳腺癌组织中高表达,检测其表达量有助于了解患者预后。
Abstract:
Objective To explore the relationship between miRNA-206 expression and clinical pathology and prognosis in invasive breast cancer tissues.Methods 121 patients with invasive breast cancer from March 2014 to May 2016 were selected as the study subjects.The expression of microRNA206 in cancer tissues was detected by RT-qPCR,and its relationship with clinicopathology and prognosis was analyzed.Results The relative expression of miRNA-206 in invasive breast cancer tissues was higher than that in adjacent tissues [(0.75±0.23)vs(0.12±0.06)],the difference was statistically significant(t=27.761,P<0.001).The relative expression of microRNA-206 in invasive breast cancer was related to TNM stage and number of lymph node metastasis(χ2=12.861,2.309,all P<0.05).The survival rates of 1a,2a and 3a in high expression group were lower than those in low expression group(78.18%,67.27% and 56.36% vs 89.39%,81.82% and 75.76%).The average survival time of patients with high expression of miRNA-206 was lower than that of low expression group [26.87 months(95%CI:23.80～29.95)vs 31.52 months(95%CI:29.34～33.69),the difference was statistically significant(χ2=5.570,P=0.018).Cox univariate and multivariate analysis showed that TNM stage,lymphnode metastasis and relative expression of miRNA-206 were closely related to the prognosis of patients with invasive breast cancer(P<0.05).Conclusion MicroRNA206 was highly expressed in invasive breast cancer.Detecting the expression of microRNA206is helpful to understand the prognosis of patients.

参考文献/References:

[1] 彭媛,程琳,王殊,等.70岁以上老年浸润性乳腺癌患者的临床病理特点、治疗现状及预后分析[J].肿瘤防治研究,2018,45(4):230-236. PENG Yuan,CHENG Lin,WANG Shu,et al.Clinicopathological features,treatment and prognosis of invasive breast cancer patients over 70 years old[J].Cancer Research on Prevention and Treatment,2018,45(4):230-236. [2] NARIMATSU R,PATTERSON B K.High-throughput cervical cancer screening using intracellular human papillomavirus E6 and E7 mRNA quantification by flow cytometry[J].Am J Clin Pathol,2005,123(5):716-723. [3] XU T P,LIU X X,XIA R,et al.SP1-induced upregulation of the long noncoding RNA TINCR regulates cell proliferation and apoptosis by affecting KLF2 mRNA stability in gastric cancer[J].Oncogene,2015,34(45):5648-5661. [4] KIM K T,LEE H W,LEE H O,et al.Single-cell mRNA sequencing identifiessubclonal heterogeneity in anti-cancer drug responses of lung adenocarcinoma cells[J].Genome Biol,2015,16(1):127. [5] 杜俊泽.miRNA-206通过调控Cx43表达对乳腺癌细胞影响及其机制的初步探讨[D].重庆:第三军医大学,2014. DU Junze.Roles of miRNA-206 in the malignant transformation of breast cancer by targeting Cx43 and its mechanism:a preliminary experimental study[D].Chongqing:Third Military Medical University,2014. [6] 陈雨欣,谭婷婷,宁明哲.乳腺癌患者血清中白介素35(IL-35)的表达及其临床意义[J].现代检验医学杂志,2017,32(2):92-94. CHEN Yuxin,TAN Tingting,NING Mingzhe.Serological interleukin-35in patients with breast cancer and its clinical significance[J].Journal ofModern Laboratory Medicine,2017,32(2):92-94. [7] SWAIN S M,BASELGA J,KIM S B,et al.Pertuzumab,trastuzumab,and docetaxel in HER2-positive metastatic breast cancer[J].New England Journal Medicine,2015,372(8):724-734. [8] POORTMANS P M,STRUIKMANS H,BARTELINK H.Regional nodal irradiation in early-stage breast cancer[J].New England Journal Medicine,2015,373(19):1879-1880. [9] 邓会岩,王心然,岳萌,等.非特殊型浸润性乳腺癌中大范围癌周间隙的出现对预后的影响[J].中华病理学杂志,2018,47(3):196-200. DENG Huiyan,WANG Xinran,YUE Meng,et al.Extensive peritumoral retraction clefts and prognosis in invasive breast carcinomas of no specific typeperitumoral spaces in non-specific invasive breast cancer on prognosis[J].Chinese Journal of Pathology,2018,47(3):196-200. [10] POORTMANS P M,COLLETTE S,KIRKOVE C,et al.Internal mammary and medial supraclavicular irradiation in breast cancer[J].N Engl J Med,2015,373(4):317-327. [11] POORTMANS P,KOUOULIAS V E,VENSELA-AR J L,et al.Quality assurance ofEORTC trial 22922/10925 investigating the role of internal mammary-medial supraclavicular irradiation in stage I-III breast cancer:the individual case review[J].Eur J Cancer,2003,39(14):2035-2042. [12] HUANG Xiaoyi,YUAN Tiezheng,LIANG Meihua,et al.Exosomal miR-1290 andmiR-375 as prognostic markers in castration-resistant prostate cancer[J].Eur Urol,2015,67(1):33-41. [13] ZARGAR H,ESPIRITU P N,FAIREY A S,et al.Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer[J].Eur Urol,2015,67(2):241-249. [14] GUPTA Y,M(¨overO)LLER S,WITTE M,et al.Dissecting genetics of cutaneous miRNA in a mouse model of an autoimmune blistering disease[J].BMC Genomics,2016,17:112. [15] GE Xi,LYU P,CAO Zhang,et al.Overexpression of miR-206 suppresses glycolysis,proliferation and migration in breast cancer cells via PFKFB3 targeting[J].Biochem Biophys Res Commun,2015,463(4):1115-1121. [16] 陈曦,李依敏,万福生.miRNA-206与肿瘤发生发展的研究进展[J].南昌大学学报(医学版),2017,57(1):97-101. CHEN Xi,LI Yimin,WAN Fusheng.Research progress of in role of miRNA-206in tumorigenesis[J].Journal of Nanchang University(Medical Sciences),2017,57(1):97-101.

备注/Memo

备注/Memo:
基金项目:重庆市科学技术攻关项目(编号:CSTC2010AC5095)。 作者简介:杨永德(1984-),男,硕士,主治医师,主要从事乳腺癌研究,E-mail:owgrq51@163.com。 通讯作者:周焱琳(1985-),女,本科,主管护师,主要从事乳腺癌健康管理,E-mail:udhtt17@163.com。收稿日期:2019-03-29 修回日期:2019-04-10
更新日期/Last Update: 2019-07-30